ChinaBio® Today is the most widely-read source for China life science news and analysis. From our offices in Shanghai and California, we provide daily news, commentary and analysis on public and private China life science companies and industry events, as well as global issues affecting the China life science industry.
Deals and Financings Sino Biopharm announced a deal worth up to $200 million to acquire a 60% stake in Softhale, a Belgium company with a novel inhaler; Chime Biologics collected $190 million in...
CASI Raises $32.5 Million for China In-Licensing Operations
March 26, 2021
CASI Pharma (NSDQ: CASI), a Maryland-Beijing company. raised $32.5 million in a private placement. CASI develops and commercializes novel in-licensed drugs in China . Earlier this month, CASI acquired...
Shanghai ImmuneOnco Biopharma completed an $89 million Series C funding led by Guangdong 's Greater Homeland Bay Area Investments and Lilly Asia Ventures. Founded in 2015, ImmuneOnco has established...
Eucure Says anti-CTLA-4 Antibody Effective in Early Tests
March 25, 2021
Beijing 's Eucure Biopharma reported "encouraging" results from an Australian Phase I trial of its anti-CTLA-4 antibody in patients with solid tumor cancers. YH001 was administered in combination with...
Deals and Financings A Sino Biopharma subsidiary out-licensed ex-China rights for a fibrosis therapy to Graviton Bio of New York in a deal worth up to $517.5 million; Yangtze River Pharma signed a...
Connect Biopharma, a Suzhou-San Diego company, raised $191 million in a NASDAQ IPO to support its portfolio of autoimmune treatments. The company's lead candidate, CBP-201, is an antibody that targets...
Chance Pharma Acquires China Rights to Inhaled PAH Therapy
March 18, 2021
WuXi Biologics Acquires 90% Stake in CBC's Suzhou CDMO
March 18, 2021
BeiGene, a Beijing oncology company, will collaborate with Shanghai 's 111 Inc. to develop an Internet + Medicine & Healthcare model to support distribution of BeiGene's products. The companies will...
ansoh Pharma entered an $122 million agreement to acquire Greater China rights to a novel antifungal from Synexis of New Jersey . The agent, ibrexafungerp, is a first-in-class, broad-spectrum...